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Abbreviations: WD: Wilson’s disease, Cu:copper, DP: d-penicillamine, TTM: tetrathiomolybdate, AST: 1 
aspartate transaminase, ALT: alanine transaminase, ACLF Acute on chronic liver failure, hepatocellular 2 
carcinoma, KF: Kayser-Fleischer , MARS: Molecular Absorption Recirculating System, TPE: Total Plasma 3 
Exchange, INR:International Normalised ratio, NWI: New Wilson's Index, PELD:Pediatric end stage liver 4 
disease, MELD: Model for end stage liver disease, LT:liver transplantation, GAS for Wilson disease: 5 
Global Assessment Scale, for Wilson disease 6 
 7 
Key words: Wilson disease, Wilson's disease scoring, modified Leipzig scoring, rare disease, genetic 8 
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 10 
  11 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
3 
 
  1 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
4 
 
Introduction  1 
This document is the outcome of a consensus meeting in March 2017 of experts from the Indian 2 
National Association for the study of Liver (INASL), The Indian Society of Pediatric Gastroenterology, 3 
Hepatology and Nutrition (ISPGHAN) and the Movement Disorders Society of India (MDSI), which 4 
represent the major sub specialties involved in the care of Wilson’s disease. The need for this was felt 5 
as most previous guidelines have either focused on the hepatic aspects (AASLD: American Association 6 
for the Study of Liver Diseases, EASL: European Association for the Study of the Liver)
1,2
 or pediatric 7 
aspects (ESPGHAN: European society of Pediatric Gastroenterology Hepatology and Nutrition)
3 
of the 8 
disease. Participants at the meeting presented recommendations on specific areas of the disease and 9 
then all members voted on them using the nominal voting technique as per standard guidelines.
4 
The 10 
quality of evidence was adapted from the GRADE (Grades of Recommendation, Assessment, 11 
Development and Evaluation) system.
5
 The final recommendations were then circulated to all the core 12 
group members and updated based on systematic literature search. These guidelines are thus 13 
comprehensive and cover all aspects of Wilson’s disease (WD). They also reflect the challenges faced 14 
by clinicians in resource-limited settings. 15 
 16 
Nominal group technique of voting 17 
Hepatologists and neurologists manage WD patients, often with overlapping disease but no joint 18 
consensus exists till date. We felt the need for practice guidelines with a holistic management. The 19 
process was primarily initiated by the first author (AN). Expert Hepatologists (pediatric and adults) and 20 
neurologists were consulted to identify the gaps in literature and difficulties in management practices. 21 
Specific questions and areas of interest were identified and distributed to the core members. A two-22 
day deliberation on WD was held on March 2017 in Mumbai. On the first day, various aspects of 23 
pathogenesis, management and recent literature review were presented and debated. On the second 24 
day, the core members met for formulating the guidelines. AN and RKD moderated the session. 25 
Presentations on specifically allotted topics were projected on the power-point by each core member. 26 
At the end of each presentation, different viewpoints were debated and finally voted. The statements 27 
were recorded. Each presenter was asked to submit the review of literature of their individual 28 
assignment by a specific deadline. The information was pooled. The draft was revised several times by 29 
AN,MSS and JM with addition and deletion of certain areas. PLK, HD and SS contributed in specific 30 
areas including the modified scoring system. The final manuscript was drafted by AN. 31 
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 1 
Historical perspective of Wilson’s disease 2 
The first possible case of Wilson’s disease  was described by Frerichs (1861) in a 9-year-old boy with 3 
movement and speech abnormalities, whose autopsy showed liver cirrhosis.  Kayser (1902) followed by 4 
Fleischer (1903) reported a greenish-brown ring around cornea in patients of suspected multiple 5 
sclerosis. Wilson (1911), described the disease as familial “progressive lenticular degeneration” in 6 
association with cirrhosis of the liver and Hall (1921) coined the term “hepatolenticular degeneration, 7 
while Umpel (1913) demonstrated increased copper (Cu) in liver and basal ganglia in patients with WD.  8 
Subsequently, Mandelbrot (1948), Scheinberg-Gitlin (1952), and Cartwright (1954) reported increased 9 
urinary copper, decreased level of ceruloplasmin and increased serum free copper respectively in WD. 10 
Bearn (1957) first postulated that it was a genetically determined metabolic disease, and Walshe 11 
(1956)
6
demonstrated treatment success with d-penicillamine (DP) (1956) and trientene (1969)
7
. 12 
Brewer first documented use of Zinc and tetrathiomolybdate (TTM)in Neuro WD.
8,9
 13 
 14 
Epidemiology of Wilson’s disease 15 
WHO estimates that the global prevalence of WD is 1/10,000 to 1/30,000.
10 
Clinical prevalence in West 16 
was estimated 5 decades ago as 5 per million.
11
 Since then, it has steadily increased to approximately 17 
142 per million by modern genetic testing. Some parts of Europe such as Romania and Sardinia report 18 
highest prevalence (370-885 per million) with 6 mutations accounting for 85% of their cohort.
12 19 
Sequencing of ATP7B in 1,000 control participants in the UK allowed the frequency of an individual 20 
carrying two mutant ATP7B alleles to be estimated at 1/7,026. In China, the prevalence is estimated as 21 
5.87 per 100,000. Newborn screening programs show disappointing results. Screening by serum 22 
ceruloplasmin in children aged 6 months to 9 years yield prevalence of 124 per million in Japan. 23 
Screening programs recommend 3 years and above as opportune time to detect the disease. 
13
In India, 24 
there are no community-based incidence and prevalence studies of WD. Among pediatric liver 25 
diseases, WD accounts for 7.6-19.7% in tertiary hepato-biliary centers. Fifteen to twenty new cases of 26 
WD are registered annually in referral neurology centers.
14
 27 
 28 
Normal copper fluxes and pools
15,16
 29 
The body contains 110 mg of Cu, predominantly in the muscles (28 mg), bones (46 mg) and connective 30 
tissue. The Cu pool in the musculoskeletal system is in constant exchange with plasma. Plasma contains 31 
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approximately 1 mcg/mL, of which 60-95% bound to ceruloplasmin. Ceruloplasmin is a source of Cu for 1 
peripheral organs where Cu is an essential cofactor for many enzymes. 2 
The copper circulation is explained in Figure 1. Normal dietary Cu intake is 1.5-5 mg in 24 hours, 50-3 
60% of which is unabsorbed and excreted in faeces. 25-40% is absorbed from duodenum, stored by 4 
enterocytes and bound to metallothioneins in a non-toxic form. From this intestinal pool, 75% flows 5 
through the portal system with albumin or transcuprein and is taken up by the liver. The remaining 6 
25% is bound to albumin in the circulation. In the liver, 20% of Cu is re-excreted back into the 7 
gastrointestinal tract through bile and 80% is transported to the periphery, bound to ceruloplasmin.  8 
The biliary excretion is approximately 2.5 mg/d. Near-similar amounts are excreted from other 9 
secretions (saliva, gastric, pancreatic and intestinal fluid). These are the endogenous Cu excretions, a 10 
large proportion (approximately 80%) is again reabsorbed by the intestinal mucosa. When copper is 11 
deficient in the diet, there is enhanced affinity of metallothioneins in enterocytes for copper, thus 12 
increasing its absorption and vice versa. Thus, the daily fecal losses are a combination of unabsorbed 13 
dietary Cu and small proportion of excreted endogenous Cu amounting to approximately 1.5-4 mg/d. 14 
Compared to fecal excretion, urinary Cu excretion is low (10–100 μg/d). The effect of dietary Cu level 15 
on urinary Cu excretion is inconsistent, with some studies reporting a small but significant positive 16 
relationship while others show no effect.  17 
 18 
Pathogenesis of Wilson’s disease
17-19,
 19 
WD is an autosomal recessive disorder that affects  the ATP7B gene (chromosome 13q) expressed in 20 
hepatocytes, kidneys and placenta which encodes for the copper transporting P-type ATPase or copper 21 
translocase ATP7B. ATP7B helps in transport of copper to the trans-Golgi network (TGN) and the biliary 22 
excretion of copper. Antioxidant protein 1, a copper chaperone helps deliver copper to the six copper 23 
binding domains in ATP7B. Binding of copper to ATP7B causes ATP hydrolysis, which supplies energy 24 
for transport of copper to the lysosome. Here copper is incorporated into ceruloplasmin, which is then 25 
released in the circulation. Levels of copper in the hepatocytes regulate the intracellular distribution 26 
and function of ATP7B. With normal copper levels, ATP7B helps in synthesis of cuproproteins like 27 
ceruloplasmin. Apo-ceruloplasmin (copper free ceruloplasmin) is less stable in circulation than holo-28 
ceruloplasmin  (copper bound ceruloplasmin). When intracellular copper is in excess, ATP7B facilitates 29 
it’s excretion into bile by exocytosis.  Mutations in ATP7B result in decreased synthesis of copper bound 30 
ceruloplasmin, impaired excretion of copper and increased cytosolic, mitochondrial and nuclear levels 31 
of copper. 32 
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Copper induced liver injury
18,19
 1 
Although not yet fully understood, a few possible mechanisms have been postulated. Increased 2 
intracellular copper induces oxidative stress leading to the production of hydroxyl radicals and reduced 3 
superoxide dismutase and glutathione which leads to damage of cellular lipids, proteins and nucleic 4 
acids. Cardiolipin, on the mitochondrial membrane has been shown to be fragmented by copper 5 
induced oxidative stress. Reversible mitochondrial recovery by chelation therapy suggests that the 6 
initial damage was possibly due to multivalent interactions/multiprotein cross linking in 7 
intermembrane space and condensations within mitochondria and various other organelles. The 8 
molecular reasons for variability of clinical symptoms and lack of genotype-phenotype relationship in 9 
WD is not yet fully elucidated. Genotype variations, gene-environment interactions and altered activity 10 
of other modifier genes have been implicated. 11 
 12 
Clinical features of Wilson’s disease 13 
Clinical features depend on the predominant organ involved (mainly liver and brain) and the disease 14 
has been reported from 3 to 85 years of age. Though copper starts accumulating soon after birth, the 15 
disease takes at least 3 years to manifest. Symptoms depend upon the site of deposition of copper in 16 
the body. Walshe et al demonstrated an age-phenotypic presentation. Hepatic presentation was seen 17 
in younger age groups (<10y: 83%; 10-18y: 52%; >18y: 24%) while neuropsychiatric presentation 18 
increased as age advanced (<10y: 17%; 10-18y: 48%; >18y: 74%). Symptom onset to diagnosis was 19 
shorter in hepatic (6 months) than neuropsychiatric presentation (18 months).
20 
Studies in children 20 
from India and Egypt have shown isolated hepatic involvement (20-54%), isolated neurological (8 - 21 
22%), neurohepatic (11 - 36%) , asymptomatic (15 - 35%), and other manifestations (0 - 22%). 
21-23
 22 
The clinical manifestations are summarized in table 1, while the prevalence from different centres is 23 
shown in table 2 24 
 25 
Hepatic manifestations 26 
Liver is the first organ to be involved due to accumulation of copper in WD predominantly manifesting 27 
in childhood and is virtually involved in all cases of Wilson’s disease.
24 
The symptoms related to liver 28 
involvement are quite varied and include  29 
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Asymptomatic WD: Has been documented in 3 - 40 % patients in various studies 
25,26
These patients 1 
have incidentally detected hepatomegaly, raised transaminases or are siblings of the index WD patients 2 
detected on screening. Majority of these cases are identified in first decade of life or in adolescence.   3 
Acute hepatitis: (10-25 % )
22, 27
This mimics acute viral hepatitis, autoimmune hepatitis and drug 4 
induced liver injury. Jaundice, anorexia, nausea, malaise, fever, pale stools and pain in abdomen are 5 
often the predominant symptoms. The biochemical investigations show conjugated hyperbilirubinemia, 6 
raised transaminases and normal or marginally low synthetic functions. It is important to consider WD 7 
in older children and adolescents with sero-negative acute hepatitis. 8 
  9 
Acute liver failure (8-20%) 
22,28 
Predominantly seen in childhood and adolescents. It is usually associated 10 
with Coomb’s negative non immune intravascular hemolysis 
29 
The presentation mimics acute hepatitis 11 
but the condition deteriorates rapidly over days to weeks and is often fatal. It results in deep jaundice, 12 
hemolysis, coagulopathy, ascites, encephalopathy and renal failure. The investigations show very high 13 
serum bilirubin, mild to moderate rise of liver enzymes, low serum alkaline phosphatase, low serum 14 
uric acid and defective synthetic functions. This phenomenon has also been reported in patients who 15 
have stopped the chelation therapy abruptly. Serum alkaline phosphatase /total bilirubin ratio 16 
<4 and  AST:ALT (aspartate ratio >2.2 combined  has been described to have a diagnostic sensitivity and 17 
specificity of  100 %.
30 
However, this has not been validated in subsequent studies
31
 18 
  19 
Acute on chronic liver failure (ACLF) (11-55%)
25,32
In two studies on ACLF from India, WD was the 20 
underlying chronic liver disease in 42 - 43 % patients with a superadded acute viral hepatitis.
33,34 
Viral 21 
hepatitis is often the acute event that deteriorates underlying hepatic WD and is the first manifestation 22 
of the disease. There is a prodrome followed by deep jaundice, early onset ascites, encephalopathy and 23 
coagulopathy rapidly progressing to a multiorgan dysfunction. 24 
  25 
Chronic hepatitis (10-30%)
35 
Seen especially in adolescents and young adults.
  
Nonspecific and 26 
constitutional symptoms such as fatigue, anorexia, nausea, malaise, may present before onset of 27 
jaundice and hepatic dysfunction. Associated delayed puberty, amenorrhea, polyarthralgia, may be 28 
present. 29 
  30 
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Cirrhosis: (35%–60%) Patients may present with complications of cirrhosis
22, 25,28
including ascites 1 
(spontaneous bacterial peritonitis), encephalopathy, and renal failure (including hepatorenal 2 
syndrome) or portal hypertension (variceal bleeding).
 36
 In adults, although neurological manifestations 3 
may dominate the underlying liver is usually cirrhotic. Any young patient more than 3 years of age 4 
presenting with cirrhosis should be evaluated for WD as an underlying cause. 5 
  6 
Fatty liver: Wilson disease should be thought of as differential diagnosis in a child less than 10 years 7 
presenting with a fatty liver where Non Alcoholic Fatty Liver Disease is less likely. Various histological 8 
and histological series report incidence from 28% - 35.7%. 
37,39
 9 
  10 
Cholelithiasis: Chronic hemolysis leads to mixed gall stones which are cholesterol predominant but also 11 
pigmented and patients may present with symptoms/complications of gall stones 
35
Copper content of 12 
the gall stone is low as these patients have defective excretion of copper into the bile.  13 
  14 
Malignancies: The development of hepatocellular carcinoma (HCC) in patients with WD is rare 15 
compared to other causes of cirrhosis. Retrospective analysis of 363 patients of WD diagnosed in UK 16 
and Sweden has shown that 4.2 – 5.3 % develop HCC or cholangiocarcinoma over a 10 – 29 years and 17 
15 % over a 39 year follow up.
39
 18 
 19 
Neurological manifestations  20 
Most patients who present with CNS manifestations have liver disease at the time of presentation, 21 
though not symptomatic.  Contrary to the initial belief that hepatic form is the predominant 22 
presentation of WD, over the years published literature has noted that neurological manifestations 23 
tend to be more common at presentation, accounting to as high as 60%.
40-42 
However, there could be a 24 
centre oriented bias in reporting depending on the speciality a patient has been referred to. Patients 25 
with neurological presentations tend to be older (second/third decade) and usually have a Kayser-26 
Fleischer (KF) ring (Figure 2).  Early or subtle neurological manifestations in young children include 27 
deterioration of handwriting and school performance, dysarthria and drooling of saliva. The classical 28 
dystonia involving the facial and mandible muscles produce a characteristic “Wilson ‘s facies”. Wilson’s  29 
facies is scored on presence of vacuous smile, open mouth, hypersalivation and dull look, a unique 30 
feature which gives an estimate of severity 
43 
(Figure 3). The presenting neurological symptoms tend to 31 
be wide and variable.  In a series of 307 patients from India,
44
 the common presenting symptoms were 32 
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: tremors (31.6%), dysarthria (15.6%), jaundice (12.4%), abnormal gait (8.8%), abdominal distention 1 
(7.8%), musculoskeletal symptoms (5.2%), seizures (4.9%), behavioural problems (4.6%), dystonia 2 
(3.6%), clumsiness (2.6%), drooling of saliva (2.6%), generalized weakness (2.3%), decreased scholastic 3 
performance (1.9%), changed sensorium (1.3%), bleeding symptoms (1.3%), dysphagia (0.9%), chorea 4 
(0.3%), and poor vision (0.3%). Over the course of disease, patients tend to develop varied combination 5 
of these presenting features.  6 
Primarily the neurological form consists of extrapyramidal manifestations, but not exclusively limited to 7 
it.
42
Broadly, the extrapyramidal neurological abnormalities can be classified as: (a) an akinetic- rigid 8 
syndrome similar to Parkinson’s disease, (b) pseudosclerosis dominated by tremor, (c) ataxia, and (d) a 9 
dystonic syndrome.  Other major neurological presentations include seizures, and cognitive changes.  10 
Seizures are not uncommon and could occur at any stage of the disease with published frequency 11 
between 4.2% to 7.5%
42
 12 
 13 
Psycho-behavioural manifestations 14 
Psycho-behavioural issues are very common in WD, and constitute almost for 1/3rd of presenting 15 
symptoms. Almost all the patients will have some form of psychiatric symptoms during the course of 16 
their disease.
45 
Amongst the psychobehavioral symptomatology, the following remain the core issues: 17 
organic dementia, psychosis, psychoneurosis and behavioral disturbances characterized by impulsivity 18 
occasionally extending to unlawful behavior.
46 
Psychotic symptoms of WD are often undiagnosed and 19 
factors like lack of awareness, failure to recognize co-existing neurological features or 20 
misinterpretation of such symptoms as side effects of neuroleptic treatment are some of the possible 21 
cited reasons. The delay in diagnosis ranges from 1 to 5 years.
47,48
The reported incidence of psychiatric 22 
symptoms as the presenting manifestation varies from 2.4% - 20%., and can be categorized into the 23 
following groups
49
 24 
Personality Changes: Personality changes include bizarre behaviour, impulsivity occasionally extending 25 
to criminal behaviour, disinhibition, irritability, emotionality, decreased threshold for anger and 26 
aggression. Bizarre behaviour and irritability are more often associated with bulbar and dystonic 27 
features rather than tremors.
42,49
 28 
Affective Disorders: Depression, is the most common psychiatric manifestation and often co-occurrs 29 
with neurological symptoms, but not with hepatic disease. In the series by Shanmugiah A et al,
50
 18% 30 
had bipolar affective disorder, 4% had major depression and 2% had dysthymia. Other affective 31 
disorders such as hypomania and mania though rare, have also been reported. 32 
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Psychosis:  "Schizophrenia-like" and other forms of psychosis can rarely be the initial 1 
manifestation, 
*
 but more commonly accompany other neurological features (16-51% )
42, 45,50 2 
Cognitive Impairment:  Mental sub-normality though not described as a feature of WD was found 3 
in 23% of patients with WD on neuropsychological and intellectual assessment.
52
 4 
Others:  Other psychiatric manifestations including substance abuse, catatonia , sexual preoccupation 5 
and anxiety disorders have also been reported.
53
 6 
Behavioural symptoms do respond to de-coppering therapy and few may require long term 7 
symptomatic behavioural pharmacotherapies.  8 
 9 
Ocular manifestations  10 
Copper accumulates in the Descemet’s membrane of the cornea forming the Kayser-Fleischer (KF) ring, 11 
which is greenish brown in colour (Figure 2). They are always bilateral and are seen in 50-60% of 12 
hepatic and 95-100% cases of neurological WD.
54 
Although sometimes visible to the naked eye, a slit 13 
lamp examination is necessary for confirmation.  They appear sequentially at the 14 
(upper>lower>medial>lateral) segment of limbus and on chelation therapy disappear in reverse 15 
direction. KF rings may mimic bile pigment rings seen in the stromal layer of the cornea in advanced 16 
cholestasis and hence need to be confirmed by an experienced ophthalmologist especially if jaundice is 17 
present.
55
 In a study by Fenu et al, partial or total KF ring resolution was observed in 28%, deterioration 18 
in 6% and static in the rest of the cohort over 1-3 years of therapy.
56
 After liver transplantation, a 19 
partial decrease in or complete disappearance of the K-F ring has been documented.
57
 20 
Sunflower-cataract is uncommon (2-17%) and is due to copper deposition in the anterior capsule of the 21 
lens.
58 
These are always associated with KF rings, do not disturb vision and disappear with chelation 22 
therapy.
54 
Abnormal oculo-motor functions are frequently seen on electro-oculography  in patients 23 
with WD but has doubtful clinical significance.  24 
 25 
Renal manifestations  26 
Tubular injury (copper deposition in epithelium of proximal and distal convoluted tubules) occurs from 27 
WD (8%) but glomerular injury (10%)is usually a complication of chelation therapy.
54 
Tubular injury 28 
manifests as nephrocalcinosis (microscopic hematuria) and nephrolithiasis (renal colic).  Though 29 
glomerular injury may be due to mesangial deposition of copper,
59 
it is more commonly related to the 30 
d-penicillamine treatment.  Hence, at presentation, all cases of WD should be screened for renal 31 
tubular dysfunction with a urine routine and microscopy, while on follow-up with chelators, proteinuria 32 
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should be assessed to detect glomerular injury. In a study of 41 patients with WD (6-37 years of age) 1 
who were on treatment d-penicillamine for 0-15 (mean 4.5) years, Sozeri et al have shown that 39% 2 
had significant proteinuria.
60
 Low molecular weight proteinuria was observed in the first 2 years of 3 
treatment, indicating early tubular damage, while high molecular proteinuria suggesting glomerular 4 
injury, persisted over longer periods. Children with tubular dysfunction need treatment with 5 
bicarbonate in addition to d-penicillamine.
61 
D-penicillamine needs to be discontinued (permanently) in 6 
those who develop glomerular injury especially if the proteinuria is in the nephrotic range.  7 
 8 
Hematological manifestations 9 
These include Coomb’s negative hemolytic anemia and thrombocytopenia with or without hemolysis. 10 
47,54 
The sudden release of excess free copper from liver due to hepatocyte necrosis produce oxidative 11 
stress on RBCs resulting in hemolysis. The hemolytic anemia may be may be mild with asymptomatic 12 
liver disease or an acute severe form heralding the development of acute liver failure.  Patients with 13 
advanced liver disease, have abnormal coagulation profile and platelet dysfunction, while 14 
splenomegaly from portal hypertension can result in hypersplenism, but none of these are specific for 15 
WD. 16 
 17 
Osseomuscular manifestations 18 
Osseomuscular symptoms may rarely be the presenting feature (2%)
40, 42, 
or occur during the course of 19 
the disease in adults. Osteoporosis (24-88%) osteomalacia (14-35%), spontaneous fractures (9-35%), 20 
rickets, osteochondritis dessicans, chondromalacia patellae, premature osteopenia and degenerative 21 
arthritis of knees and wrists have been reported in the second and third decade of life.
62,63 
Though 22 
osteoporosis has been documented on densitometry in 43-67% of patients with WD,
64
most patients 23 
are asymptomatic with only radiological abnormalities in the large joints.  Except chelation, there is no 24 
other specific treatment available for osseo-muscular disorders in WD. Paradoxically, D-penicillamine 25 
itself can induce rheumatological disorders like systemic lupus erythematosus, Good-pasture 26 
syndrome, myasthenia, dermatomyositis etc.
64 
The cause for osseomuscular symptoms is unclear, 27 
though symptoms improve with chelation and in vitro studies have documented abnormal copper 28 
deposition in cartilage and bones. Complete reversal of joint manifestations following liver 29 
transplantation has been documented in a case report from India.
65
 30 
 31 
Other manifestations 32 
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Asymptomatic cardiac arrhythmias are quite common in WD. Cardiomyopathy, autonomic dysfunction 1 
and cardiac deaths due to copper accumulation in cardiac tissue have occasionally been reported in 2 
WD. Kuan et al
66
 reported ECG abnormalities in 34%, which include left ventricular hypertrophy, ST 3 
wave depression and T wave inversion. Asymptomatic orthostatic hypotension was reported in 19%, 4 
abnormal response to Valsalva in 33% and cardiac deaths in two cases (ventricular fibrillation and 5 
cardiomyopathy in one each). 6 
Extensor hyperpigmentation due to increased melanin has been reported in 11% of WD patients.
67
 7 
Blue lunulae of nails (azure lunulae) and acanthosis nigricans have occasionally been reported in WD.
54 8 
Endocrine abnormalities reported include amenorrhea, gynecomastia and testicular atrophy. 9 
Additional features include pancreatic insufficiency, diabetes mellitus, gigantism and 10 
hypoparathyroidism 
68
 11 
 12 
 13 
CONSENSUS STATEMENTS ON CLINICAL FEATURES  14 
Hepatic manifestations  15 
1. Isolated hepatic involvement is more common in childhood and adolescence than adulthood 16 
demonstrating an age-phenotypic nature of the disease. (Strength 1, Level of evidence A).  17 
2. Cirrhosis and portal hypertension is a common presentation in hepatic WD (Strength 1, Level 18 
of evidence B).   19 
3. Acute liver failure, acute on chronic liver failure, acute hepatitis, asymptomatic 20 
hypertransaminasemia, fatty liver, cholelithiasis and rarely hepatobiliary malignancies are 21 
the other manifestations of hepatic WD (Strength 1, Level of evidence B).   22 
4. Concomitant hemolysis is invariably seen in patients of WD presenting with acute liver failure 23 
(Strength 1, Level of evidence C).    24 
Neuropsychiatric manifestations  25 
1. Neurological / Neuropsychiatriac symptoms can be the sole presenting clinical symptom of 26 
Wilson’s disease. (Strength 1; Level of Evidence – A)  27 
2. Neuropsychiatric form of Wilson’s Disease usually tends to present later than the hepatic form 28 
(Strength 1; Level of evidence – B)  29 
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3. The clinical symptomatology varies significantly affecting various neurological domains, 1 
including from mild tremors, dystonia, seizures, Parkinsonism, ataxia, cognitive changes and 2 
frank behavioural issues.  (Strength 1; Level of evidence -A) 3 
4. Any Child / Young adult presenting with neuropsychiatric features, screening for Wilson’s 4 
disease should be considered. (Strength -1, Level of evidence -A) 5 
 Ocular manifestations 6 
1.  KF rings are usually bilateral and present in almost all cases of neurological and more 7 
than half of hepatic WD. Slit lamp examination is mandatory for diagnosis (Strength – 1 8 
Level of evidence – B)  9 
2. Sunflower cataract is uncommon, even in neurological WD. (Strength – 1 Level of evidence 10 
– B)  11 
3. Disappearance of KF rings often correlates with adequate chelation, but may take years 12 
(Strength -1, Level of evidence –B)  13 
Renal manifestations  14 
1. Renal tubular dysfunction with nephrocalcinosis (manifesting as microscopic hematuria) is 15 
not uncommon in Wilson disease. (Strength-1, Level of evidence –B)  16 
2. Children on d-penicillamine should be periodically evaluated for proteinuria to detect drug 17 
induced glomerular injury. (Strength-1, Level of evidence -B) 18 
Hematological manifestations 19 
1. Mild Coombs negative hemolytic anemia can occur in asymptomatic WD. (Strength-2, 20 
Level of evidence -C)  21 
2. Acute severe hemolysis can be an initial manifestation of acute liver failure related to 22 
WD. (Strength-2, Level of evidence -C)  23 
3. WD should be suspected in adolescents and young adults with Coombs negative 24 
hemolytic anemia. (Strength-2, Level of evidence C)  25 
Other system manifestations  26 
1.  Joint manifestations may the presenting symptoms of Wilson’s disease. Precocious onset 27 
degenerative joint disease (osteoarthritis, chondrocalcinosis) in 2
nd
 and 3
rd
 decade should raise a 28 
suspicion of WD. (Strength-2, Level of evidence -B)  29 
2. Asymptomatic arrhythmias are common and so a cardiac evaluation may be routinely done in all 30 
adult patients. (Strength-1, Level of evidence -B) 31 
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 1 
Diagnosis of Wilson’s disease 2 
A combination of serum ceruloplasmin, KF rings and 24-hour urine copper is most commonly used to 3 
diagnose WD. Liver biopsy and estimation of dry copper has been traditionally thought to be of value in 4 
doubtful situations.  Extrapyramidal symptoms associated with KF ring makes the diagnosis of WD 5 
certain. Genetic mutation studies are now available. 6 
 7 
Serum ceruloplasmin 8 
Ceruloplasmin is a carrier protein produced mainly by the liver for the transport of copper in blood. A 9 
low level in a person with suspected disease may be suspicious of WD. The youngest age for testing 10 
serum ceruloplamin to diagnose WD is 1 year.
3
 Enzymatic assay which measure copper dependent 11 
oxidase activity and antibody dependent immunologic assays such as radioimmunoassay, radial 12 
immunodiffusion, or nephelometry have been used to measure ceruloplasmin levels. Although the 13 
enzymatic method is superior and the preferred method for estimation, the immunological -14 
 nephelometry method is the more commonly available method of measurement.
71,72,70 
Normal values 15 
range from 20 to 40 mg/dl. While values <10 mg/dl strongly favour the diagnosis of WD, those between 16 
10-20 mg/dl may be seen in both patients and about 20% of heterozygotes.
73
 However, normal values 17 
may be seen in up to a third of patients with WD and  may be falsely normal in acute inflammation 18 
(ceruloplasmin is an acute phase reactant). Serum ceruloplasmin is typically lower in neuro-psychiatric 19 
disease compared to liver disease.
74 
Ceruloplasmin levels may be decreased in patients with other 20 
causes of cirrhosis, malabsorption and renal disease. Low serum ceruloplasmin levels alone cannot be 21 
relied upon to make a diagnosis of WD, although very low levels below 5 mg/dl are highly suggestive of 22 
WD  23 
24- hour Urinary copper assay 24 
This is a sensitive test that indirectly reflects the serum free copper level. Urine sample must be 25 
collected in a copper free container and the test should be done before chelators are started. It is an 26 
excellent test in symptomatic patients, but may be false negative in those who are asymptomatic.
75, 76   27 
A level >100 mcg/dl is considered virtually diagnostic, but recent studies have shown that lowering the 28 
cut off levels to 40 mcg/dl for asymptomatic patients increases the sensitivity.
76
 The assay is difficult to 29 
perform and should be done only in reliable laboratories   30 
 31 
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D-penicillamine challenge test (PCT) 1 
After a base line 24-hour collection for copper assay, a second 24 hour sample of urine is collected 2 
while the patient is given two 500 mg doses of -D-penicillamine 12 hours apart. Earlier considered to be 3 
a useful test in diagnosis, it is not recommended now in view of the high false positive results.
77 4 
Lowering the threshold for basal urine copper excretion together with measurement of serum 5 
ceruloplasmin and KF ring may be more useful rather than PCT.
78
 6 
  7 
Kayser-Fleischer Rings  8 
Kayser Fleischer (KF) ring should be sought in all patients suspected to have WD.
76
 This test may be 9 
negative in asymptomatic siblings or children less than 10 years of age. These are best seen on 10 
conventional slit lamp examination. A hand held slit lamp apparatus may be used in patients who are 11 
not ambulatory. 12 
  13 
Serum copper 14 
Measures the total serum copper (ceruloplasmin bound copper + non-ceruloplasmin copper or “free 15 
copper”) Ninety percent of the serum copper is bound to ceruloplasmin. 16 
Total serum copper does not reflect tissue levels and therefore unreliable in diagnosis. Serum free 17 
copper may have a better correlation, especially in patients with acute liver failure. However, the value 18 
of free copper is limited as it relies on the accuracy of tests measuring serum ceruloplasmin and  serum 19 
copper.
24
 20 
Serum exchangeable copper  21 
This test corresponds to the copper which is bound to albumin and other peptides. A cut off value of 22 
15%  of relative exchangeable copper (namely exchangeable copper to serum copper ratio) has been 23 
reported to have 100% sensitivity and 100% specificity for the diagnosis of WD in adults.
79
 24 
Coomb’s negative hemolytic anemia 25 
The presence of significant hemolysis on peripheral smear and a negative Coomb’s test in a patient 26 
with acute liver failure makes the diagnosis of Wilson’s disease highly likely.
24
 Hemolysis contributes to 27 
the elevated serum bilirubin levels and a decrease in hemolysis reflects in a commensurate drop in 28 
serum bilirubin.
2
 29 
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  1 
Liver biopsy and liver copper estimation 2 
Histopathological changes are not specific for WD and range from steatohepatitis, interface hepatitis, 3 
chronic hepatitis with Mallory’s hyaline, bridging fibrosis and cirrhosis, most of which are seen with 4 
other liver diseases as well.
80
 5 
 Although orcein, rhodamine and Timm’s stain have been used to identify liver copper, the distribution 6 
is patchy and interpretation is difficult. Positive staining may be seen in diseases associated with 7 
impaired bile secretion.
81
  These can be supportive evidence rather than of primary diagnostic 8 
importance. 9 
Liver copper estimation 10 
Often described as gold standard test for WD, it is not easily available and may be fraught with logistic 11 
and quality issues. Biopsy specimens for estimation of copper should be sent in a dry condition in a 12 
copper free container for atomic absorption analysis,
81
 although paraffin embedded specimens can 13 
also be analysed for copper. The normal copper content in liver tissue is <50 mcg/g of dry weight while 14 
in WD a level > 250 mcg/g is commonly encountered even in asymptomatic individuals. The copper 15 
level tends to be higher in those with liver dysfunction compared to those with neurological or 16 
asymptomatic disease. Liver copper content is physiologically increased in infancy
82
Uneven distribution 17 
of copper in the liver and low levels of copper in regenerating  nodules limits its usefulness in those 18 
with cirrhosis and late stages of WD. In addition, patients with cholestatic liver disorders can have a 19 
high liver copper.
83,84
 20 
 21 
MRI brain 22 
The presence of neurocognitive features in conjunction with KF ring is often sufficient to make the 23 
diagnosis of WD. Accumulating experience has demonstrated MRI abnormalities to be almost universal 24 
in those with neurological disease. In one study, the MRI features with WD included "Face of giant 25 
panda" (14.3%), tectal plate hyperintensity (75%), central pontine myelinolysis -like abnormalities 26 
(62.5%), and concurrent signal changes in basal ganglia, thalamus, and brainstem (55.3%).
85
 These 27 
features when present are virtually pathognomonic of WD.
86
(Figure4) 28 
Family history 29 
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A positive family history of WD (including deaths from compatible liver or neurologic disease) is useful 1 
especially when parental consanguinity exists. A recent study from Vellore, India identified 2 
consanguinity in 44% of patients with WD.
87 3 
 4 
Genetic studies 5 
WD is an autosomal recessive disease and in 1993, two separate teams reported mutations in ATP7B 6 
gene on chromosome 13. Over 600 mutations have since been described and genetic studies have 7 
gradually become part of routine tests in diagnosis.  The international consensus diagnostic score 8 
(Leipzig score 1993) gave maximum weightage to genetic testing.
88 
Within families, the risk of Wilson’s 9 
disease among siblings of an affected individual (“ the proband” or index patient) is 25%, while among 10 
the progeny the risk is 0.5%.
89 
If ATP7B mutations have been identified in a patient with Wilson’s 11 
disease, genetic testing to look for these mutations in his / her pre-symptomatic siblings is valuable to 12 
differentiate heterozygote carriers from homozygotes or compound heterozygotes for Wilson’s 13 
disease. Other copper related liver disorders (Indian childhood cirrhosis, atypical copper cirrhosis)
90 14 
also can be differentiated with mutation studies. H1069Q mutation is the commonest mutation seen in 15 
over 50% of patients in Western countries is almost non-existent in other countries like India.
91,92 16 
Despite the high rate of consanguinity noted in Indian families that are affected, there is a wide 17 
spectrum of mutations observed. This phenomenon can be considered as an ‘Indian paradox’.
93
 Various 18 
studies suggest that p.C271X may be the commonest mutation in patients from Western part of India 19 
patients
94 
and p.G1101R
95
 maybe the commonest mutation in patients from Eastern parts of India with 20 
Wilson’s disease. C813A was identified in 19% of patients from East India and 12% of patients from 21 
South India.
96
 Studies have not been able to establish significant correlation between the ATP7B 22 
mutations and Wilson’s disease phenotype. The large number of ATP7B mutations adds to the 23 
complexity of this correlation. It is also recognized that affected siblings within a family (who share the 24 
same Wilson’s disease genotype) may have different phenotypes.
93
 It is still unclear what determines 25 
whether a patient with Wilson’s disease will develop hepatic or neurological disease or both. Looking 26 
for mutations in all 21 exons of ATP7B gene is an expensive and daunting challenge with conventional 27 
genetic tests. In addition, many patients with Wilson’s disease are compound heterozygotes. Earlier, 28 
mutation screening was performed to identify exons likely to harbor mutations as a preliminary step 29 
(using single strand conformational polymorphism
97
 or conformation sensitive gel electrophoresis
*
) 30 
and then sequencing only the selected exons as a second step. Technological advances now enable 31 
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simultaneous analysis for mutations in all 21 exons of ATP7B gene using microarray based tests
98
 or 1 
next generation sequencing.
96
 2 
Regional centres need to be established where these tests can be done at an affordable cost with a 3 
quick turn - around time. There is also a need for a nationwide network in various countries to 4 
determine the common mutations in each country. 5 
Prenatal testing for WD is technically feasible.
97
 However, since it is an easily treatable disease, routine 6 
prenatal screening for Wilson’s disease does not appear justified. 7 
 8 
Rationale for a new scoring system for diagnosis of WD (modified Leipzig score)  9 
The Leipzig scoring system for diagnosis of WD
88
 was modified by the consensus group members by 10 
adding points for a family history or sibling deaths with phenotypes consistent with WD. It was 11 
subsequently validated in 70 patients of proven Wilson’s disease. This modified Leipzig score (Table 3) 12 
lays more importance to simple variables that are easily available. As alluded to earlier, liver copper 13 
estimation is not easily available and may have methodical flaws. It was therefore excluded from the 14 
scoring system. Mutational assay may be performed for individuals in whom diagnosis is difficult to 15 
establish by clinical and biochemical testing. Further, unlike in the West there are no common 16 
mutations in India. There are more than 600 that have been identified in other parts of the world 17 
including India.  Additional weightage was given to a ceruloplasmin value of <5 mg/dL for higher points 18 
as compared to ceruloplasmin >5 mg/dL. Penicillamine challenge test also has been omitted from the 19 
modified scoring system due to poor yield and inadequate validation.  20 
 21 
Family screening 22 
Family screening of first degree relatives of WD has multiple advantages: 1) it allows early detection of 23 
disease in presymptomatic phase before a devastating course, 2) makes the family wiser and the 24 
physician more prepared and 3) identifies a healthy family member or a heterozygote carrier who can 25 
be a potential donor for living related LT should a diseased member require LT in future. Ideally family 26 
screening should include siblings, parents of affected children and offspring of affected parents.  There 27 
is 25% chance of siblings carrying the homozygous disease gene. Screening is deferred till 2 years of age 28 
when presymptomatic patients can be started on chelation therapy. Screening can be initiated earlier if 29 
any stigmata of liver disease or occult warning signs are detected (eg: hepatomegaly or fatty or nodular 30 
liver sonologically in the absence of deranged liver function tests). Histological liver fibrosis as young as 31 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
20 
 
4 month old has been documented.
99 
Assessment should include good history, physical examination 1 
including slit lamp examination of KF ring, serum ceruloplasmin, liver function tests, 24 hr urinary 2 
copper. The role of testing for ATP 7B mutation or haplotype studies assumes importance if the 3 
affected individual is alive or sample is stored before death where the specific mutation seen in the 4 
index case can be looked for in the family member being screened. Genetic testing is the only reliable 5 
method to separate heterozygote from homozygote siblings. There is however difficulty in diagnosing 6 
heterozygote carriers with certainty. Though next-generation sequencing (NGS) is promising in 7 
detecting both mutant alleles in 95%, the limitations include missing molecular defects outside the 8 
coding regions and detecting Variants of Unknown Significance (VUS) which may not be of clinical 9 
significance.
3
 More recently relative exchangeable copper (REC) appears to be a promising tool for 10 
family screening in WD, especially for heterozygous ATP7B carriers who could present with slight 11 
biological abnormalities. However further and larger studies are required to validate the same.
100
 12 
 13 
CONSENSUS STATEMENTS ON DIAGNOSIS OF WILSON’S DISEASE  14 
Serum ceruloplasmin 15 
1.    Ceruloplasmin value of < 10 mg/dl strongly favors the diagnosis of WD (Strength 1, Level of 16 
evidence B) 17 
 2.    Borderline or normal levels do not exclude the diagnosis and further tests are needed for 18 
confirmation WD. (Strength 1, Level of evidence A)  19 
3.    Values above normal are unlikely in WD (Strength 2, Level of evidence A) 20 
24 hour  urine copper  21 
1.    A basal 24-hour level >100 mcg is a very useful diagnostic test in symptomatic patients (Strength 22 
1, Level of evidence A) 23 
 2.    Lower levels (>40 mcg) have been recommended especially for asymptomatic siblings but is less 24 
specific (Strength 2, Level of evidence A)  25 
3.    D-penicillamine challenge test is not standardized, gives high false positive results and should not 26 
be used in diagnosis. (Strength 2, Level of evidence A)  27 
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KF rings 1 
1.    KF ring is highly specific for WD, but its absence does not rule out the diagnosis (Strength: 1, Level 2 
of evidence A) 3 
 2.    While it is almost always present in patients with neuropsychiatric disease only 50-60% of 4 
those with liver disease have a KF ring (Strength 1, Level of evidence A)  5 
3.    A slit lamp examination by an experienced ophthalmologist is necessary for confirming or ruling 6 
out a KF ring (Strength 1, Level of evidence A)  7 
Serum copper  8 
Serum total copper has no role in diagnosis of WD. (Strength 1, Level of evidence A)  9 
Hemolytic anemia 10 
1.  Any degree of hemolysis in the setting of liver disease that is Coombs negative heightens the 11 
suspicion of WD (Strength 2   Level of evidence A)  12 
2. The presence of significant hemolysis in an individual with acute liver failure is almost always due 13 
to WD (Strength 2, Level of evidence A)  14 
Liver biopsy and liver copper 15 
1.    There are no histopathological features pathognomic for WD (Strength 2, Level of evidence A)  16 
2.    Liver copper estimation has limited usefulness due to nonavailability of the test as well as logistic 17 
and quality issues. (Strength 2, Level of evidence A)  18 
3.    Histochemical stains for copper may only provide supportive evidence for diagnosis of WD 19 
(Strength 2, Level of evidence B)  20 
MRI brain 21 
MRI of brain with certain features such as tectal plate hyperintensity are pathognomonic of 22 
WD (Strength 2, Level of evidence B)  23 
Family history 24 
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1. Positive Family history is an indirect evidence of WD (Strength 2, Level of evidence C)  1 
2. A history of sibling death in patient with features suggestive of WD features makes WD 2 
diagnosis likely although the presence of other associated features strengthens the diagnosis. 3 
(Strength 2, Level of evidence C) 4 
  5 
 Genetic studies 6 
1. ATP7B mutation analysis is recommended as a clinical diagnostic test to support the diagnosis 7 
of Wilson’s disease in a patient suspected to have Wilson’s disease.  (Strength - 1, Level of 8 
evidence - B) 9 
2. Genetic testing for Wilson’s disease is recommended as a clinical diagnostic test in siblings of 10 
a proband with Wilson’s disease, especially if ATP7B mutation is identified in the proband. 11 
(Strength - 1, Level of evidence - B)  12 
3. Routine prenatal diagnosis of Wilson’s disease is not recommended. (Strength - 1, Level of 13 
evidence - C)  14 
Family screening  15 
Family screening of patients diagnosed with Wilson Disease is recommended: (Strength - 1, Level of 16 
evidence - A) 17 
 18 
Drug Therapy  19 
D-penicillamine (DP) 20 
DP is the preferred standard therapy for WD. It is rapidly absorbed from the intestine, bound to 21 
plasma proteins and more than 80% is excreted in the urine.
101 
DP binds to copper through 22 
disulfide bonds and every gram promotes urinary excretion of 200 mg of copper. It also induces 23 
hepatic metallothionein, a cytosolic metal-binding protein that sequesters copper, and renders 24 
it non-toxic. Clinical and biochemical improvement usually occurs within a year of treatment, 25 
but hepatic synthetic functions may take up to 10 years to normalise.
102 
Hepatic Cu levels fall 26 
during the first year, but remain above normal for several years. DP chelates several heavy 27 
metals, not just copper and has many adverse effects necessitating discontinuation in up to 30% 28 
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of WD patients (Table 3). Despite the serious adverse effects, DP is still the primary drug for 1 
management of hepatic WD in view of its time-tested efficacy, easy availability and reasonable 2 
cost.  3 
In neurological WD, a paradoxical worsening of symptoms is occasionally observed after starting DP- . 4 
While most centres report an incidence of 10%, one study by Brewer et al reported it in 50% of 5 
patients.
103 
DP  is therefore started at the lowest possible dose in neurological WD . It may be initiated 6 
as 250 mg on alternate days. There is no definitive protocol on the rate of dose escalation. While some 7 
centres increase by 250 mg every two to three weeks, others do so every month, until the maximum of 8 
1000 to 1500 mg /day in 2 or 3 divided doses is reached. The gradual increase in dose should be done 9 
under clinical and biochemical monitoring. Similarly rapid re-administration of the drug in patients who 10 
have stopped therapy for a long time may lead to irreversible neurological changes.
104,105
 The 11 
paradoxical worsening with treatment has been attributed to sudden mobilization of free copper from 12 
neurological tissues. Neurological improvement is much slower and usually reaches a plateau after 13 
around 2-3 years of treatment.  Lack of improvement in neurological status (e.g. dystonia) may be due 14 
to permanent neurological damage (putaminal necrosis). 15 
The dose of DP is 20mg/kg/day in children, while adults receive 750-1500mg per day in 2-3 divided 16 
doses on an empty stomach. Food reduces its absorption by 50% and so food should not be given 1 17 
hour prior to and 2 hours after the drug. Antacids and iron also significantly reduces absorption. 18 
Pyridoxine deficiency can occur with therapy due to inhibition of pyridoxine kinase enzyme. Hence 19 
vitamin B6 should be supplemented at a dose of 20 -40 mg in children, pregnant women and patients 20 
with malnutrition and intercurrent illness.
106
 Treatment with DP results in massive and rapid 21 
cupriuresis (> 1000ug/day) in the initial months of therapy, falling to 200–500ug/day during the  22 
maintenance period.  23 
Significant adverse effects are reported in 10 to 30 % of patients on DP therapy (Table 4). 24 
Children seem to tolerate the drug better than adults
26,107 
In a series of 74 children from UK, the 25 
reported incidence of side effects was 38 % and in 16 % the drug had to be switched over to trientine.
78 26 
Manolaki et al in their series of 54 children have reported a similar incidence of side effects at 16 % 27 
where the initial treatment with DP had to be discontinued because of the adverse effects.
108
If early 28 
hypersensitivity reactions occur, the drug should be stopped immediately. If the manifestations are 29 
only dermatological, DP can be introduced under cover of steroids. Once the skin lesions resolve, 30 
prednisolone is given initially at a dose of 0.5 mg /kg /day for 2-3 days. DP is then introduced at a low 31 
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dose of 5 mg /kg /day and increased gradually while prednisolone is tapered and stopped. However, if 1 
the manifestations involve the bone marrow (agranuloctytosis, aplastic anemia) or other organ 2 
systems, then DP should be stopped. Development of significant proteinuria or glomerulonephritis 3 
warrants stoppage of the drug. Direct dose dependent adverse effects of DP is due to the interference 4 
with copper –dependent enzyme lysyl oxidase which mediates collagen cross linkage and elastin 5 
formation leading to progeria like skin lesions, cutis laxa and elastosis  perforans serpiginosa. (EPS) 
109
 6 
(Figure 5) These usually occur when prolonged treatment is given in large doses.  7 
Trientine 8 
Trientine (Triethylene-tetramine-2-hydrochloride), is a chelator with a mechanism of action similar to 9 
DP, with fewer adverse reactions.  The dosage is 750-1500mg/day in 3 divided doses on empty stomach 10 
in adults (20mg/kg/day in children). Although trientine has traditionally been used for patients 11 
intolerant to DP,
110 
recent studies suggest that it can be used as a first line drug.
111,112 
 There are no 12 
clinical trials comparing the relative superiority of one over the other. In most developing countries 13 
including India, it is only imported for select patients since it is prohibitively expensive. It is heat 14 
sensitive and has to be stored in tightly closed containers between 2-8 degree Celsius. It chelates iron 15 
and other heavy metals as well, hence treated subjects should be monitored for iron deficiency.  16 
Trientine can also cause paradoxical worsening in neurological WD, Hence, it should be started in low 17 
doses and increased slowly similar to DP. 18 
Zinc  19 
Zn acts by inducing metallothionein in enterocytes which preferentially binds absorbed Cu, sequesters 20 
it in the enterocytes and prevents its entry into the portal circulation.
113-115
 As the enterocytes are 21 
naturally sloughed into the lumen, copper is excreted in the faeces. Zinc also induces metallothionein 22 
in hepatocytes and protects against Cu toxicity. Unlike DP and trientine, Zn acts by increasing the faecal 23 
excretion of Cu.  However, Zn has a slow action and takes much longer to achieve a negative Cu 24 
balance as compared to chelation therapy, and hence may be less effective as first line therapy in 25 
symptomatic liver disease. Although all three salts - acetate, sulphate and gluconate are effective, 26 
acetate salts are preferred due to lesser incidence of gastric side effects.
116 
Adults require 150 mg/day 27 
of elemental zinc in three divided doses while children and  those under 50 kg, are given only 75 28 
mg/day.  Zinc should be taken on empty stomach to ensure better absorption. Besides clinical and 29 
biochemical improvement, treatment efficacy is determined by a 24-hour urinary copper excretion less 30 
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than 100 µg. Urinary excretion of zinc should be more than 2000 µg/day to ensure compliance and also 1 
to determine the quality of the zinc preparation used. Zinc is used as first line drug in pre-symptomatic 2 
patients or symptomatic patients with neurological WD and for long term maintenance therapy in 3 
others after optimal de-coppering with chelators.
117-119 
In a recent study, hepatic treatment failure 4 
occurred more frequently on zinc therapy than chelator therapy. Patients who did not respond to zinc 5 
therapy showed hepatic improvement after reintroduction of a chelating agent. This suggests that 6 
chelating agents are better first line medications in symptomatic hepatic WD.   7 
 8 
Ammonium Tetrathiomolybdate 9 
Ammonium tetrathiomolybdate, originally used to treat copper poisoning in veterinary practice is a 10 
chelating drug with anti-angiogeneic properties.
120-1211
 If ammonium tetrathiomolybdate, is taken after 11 
meals, it binds to the copper in the food, thus preventing its absorption.  If taken on empty stomach, it 12 
is absorbed into the blood and forms a complex with circulating copper preventing cellular uptake; 13 
leading to its excretion in urine. The dosage used is 20 mg three times a day with meals and 20 mg 14 
three times a day in between the meals. Due to its aggressive chelating effects, the reported side 15 
effects of ammonium tetrathiomolybdate includes paradoxical worsening, bone marrow suppression, 16 
and hepatotoxicity.  However, it has been stated that the potential neurological deterioration and side 17 
effects are lesser in comparison to trientine.
122,123 
Currently ammonium tetrathiomolybdate is not 18 
available in India in many countries. Ongoing phase -2 multicenter trials with a more stable form of a 19 
chelator for copper (bis-choline tetrathiomolybdate (WTX101) report that 57% patients show 20 
improvement in liver function test and 72% show improvement in free copper levels by week 24 of 21 
therapy.
124
 Further data on the use of this drug for various phenotypes of WD is awaited 22 
 23 
Treatment phases  24 
Initial phase  25 
This phase aims to reduce the body copper levels to sub-toxic threshold. The choice is between 26 
chelators (DP or trientine) alone, zinc alone, or a combination of both. There are no randomised 27 
controlled trials comparing the three and each centre uses a protocol based on their experience and 28 
patient compliance.
2,125
 29 
DP has traditionally been the drug of choice unless the patients develop intolerance, in which case 30 
trientine is the preferred drug. In a study comparing DP versus zinc sulfate as first-31 
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line therapy for Neuro-WD, the neurological worsening on DP vs zinc within 180 days of starting the 1 
drug was 35% vs 19%.
126 
Authors concluded that DP and zinc sulfate were both effective in the majority 2 
of Neuro-WD patients. Neither therapy appears to be clearly superior. Therefore, zinc may be 3 
considered a reasonable alternative to DP as a first-line therapy. Centres using both chelator and Zinc 4 
together believe that DP has most beneficial effect in the early de-coppering phase, while zinc is 5 
inexpensive and assists by preventing copper absorption. There is insufficient data to prove the 6 
superiority of combination therapy but if it used, the two drugs must be given 6 hours apart to prevent 7 
chelation of zinc by the chelator.  8 
Maintenance Therapy  9 
This is life long and prevents copper re-accumulation after the patient has been effectively de-10 
coppered.  Zinc, in view of its good efficacy, low cost and toxicity, is the drug of choice.  DP in low dose 11 
is an alternative but patients should be monitored for side effects.
 12 
 13 
Pre-symptomatic patients 14 
An asymptomatic sibling diagnosed to have WD by biochemical or genetic testing should be treated to 15 
prevent symptomatic disease. Zinc is the drug of choice. If a neonate is diagnosed to have WD based on 16 
genetic testing, it is unclear when treatment should be started. Because of the risk of body copper 17 
depletion, it should probably not be started in the first year.
3
 It may be suggested that since clinical 18 
presentation is rare below 3 years, zinc therapy could start at the age of 2 years.  19 
 20 
Wilson’s disease presenting as acute liver failure (ALF) with / without encephalopathy 21 
Patients with encephalopathy should be considered for urgent liver transplantation. DP/trientine with 22 
or without zinc may be started as an ad hoc measure, but survival is unlikely without transplantation.  23 
In patients without encephalopathy, the decision on transplantation should be individualized after 24 
discussion with the relatives. While delay carries the risk of sudden deterioration, encephalopathy and 25 
death, unnecessary surgery may mean removing a native liver that may have recovered with medical 26 
treatment. The fulminant presentation with intense jaundice, hemolytic crisis and rapid deterioration 27 
of hepatic encephalopathy rarely survive without a transplant. Rapid removal of free copper through 28 
Molecular Absorption Recirculating System (MARS) or Total Plasma Exchange (TPE) can benefit patients 29 
with fulminant presentation. TPE efficiently removes both ceruloplasmin-bound and albumin-bound 30 
copper and the fresh frozen plasma used for exchange can be helpful in treating the associated 31 
coagulopathy. MARS is also effective 
127,128
 but more expensive and less widely available than TPE.
129
 32 
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These modalities are seen as bridge to LT, rather than a definitive treatment option.
130 
In a recent 1 
study,  9 of 10 patients of WD, apharesis was a successful bridge to transplantation.  2 
Liver transplantation  3 
Liver transplantation for Hepatic Wilson’s disease 4 
Durand et al. in 2001 reported that early administration of DP may avoid LT for a vast majority of 5 
patients (90%) presenting with fulminant WD without HE at admission.
102 
In 2006 Nazer’s score
131 6 
(serum bilirubin, INR and serum albumin) was modified to add two parameters (AST and WBC count) to 7 
the score and renamed it as New Wilson’s Index (NWI). A NWI score  ≥ 11 (table 5) was associated with 8 
non-survival without liver transplantation.
77 
In a study from South India,
132
 NWI and PELD/MELD were 9 
found to have modest accuracy in predicting outcome in WD. The authors derived a formula from 10 
regression analysis based on hepatic encephalopathy and bilirubin to predict the outcome in a 11 
fulminant presentation WD. Similarly, Fischer et al
133 
identified 3 of the 6 patients who had NWI scores 12 
predictive of death and of these 3, 2 survived without a transplant. They cautioned about the scores 13 
not being accurate and this subgroup needing further study. 14 
A recently published multi-centric cohort (comprising of 75 adults and 56 children) from France,
134
  the 15 
Kaplan Mier survival analysis revealed good 5-year survival post LT (86% - 96%) depending on whether 16 
transplants were performed before or after the year 2000. This reflects improvements in the selection 17 
of patients and peri-operative management.  18 
Liver transplantation for Neurological WD 19 
The indications for LT in neurologically affected patients is controversial. In a French study,
134
 only 6% 20 
received a LT for a purely neurological indication and these patients were significantly worse after LT 21 
when compared to hepatic patients. All three patients with severe axial Parkinson’s syndrome died 22 
(from infection) with a functional graft but without any neurological improvement. Although there is 23 
evidence that mild to moderate neurological involvement may improve after LT,
135
 neuropsychiatric 24 
disease is a predictor for poor outcome after LT.
136 
In a retrospective Italian study, neurological 25 
symptoms significantly improved after liver transplantation, but the survival of patients with hepatic 26 
and neuropsychiatric disease was significantly lower than those with liver disease alone. 
135
 27 
Sepsis was the main cause of death since neurological sequelae led to lack of ambulation and 28 
bedridden patients. LT as a treatment option for those with only neuropsychiatric disease is not 29 
recommended. 30 
Liver grafts from heterozygous donors (siblings/parents)  31 
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These are safe for both recipient and donor and disease recurrence risk is almost non existent. In 1 
developing countries like India where deceased donor liver transplant program is still evolving and 2 
most transplants are from heterozygous related donors 3 
 4 
Treatment monitoring  5 
Patients should be regularly monitored for ensuring compliance, efficacy of therapy and early 6 
recognition of side effects. Effective de-coppering (table 6) is assessed on 24- hour urine copper and 7 
serum free copper value. Serum free copper is calculated by the formula (serum copper - 3 x serum 8 
ceruloplasmin. If serum ceruloplasmin is not measured by the enzymatic method then this free copper 9 
calculation is not reliable. A 24- hour urine protein is estimated for renal toxicity of DP. This is initially 10 
done after a month, then 3 monthly and subsequently 6-12 monthly.  11 
In hepatic WD, clinical improvement is characterised by decreasing jaundice, ascites, and portal 12 
hypertension. Complete blood counts and liver function tests are performed initially after a week, then 13 
at 2 and 4 weeks followed by 3 months, 6 months and then yearly. Child Pugh score (based on serum 14 
bilirubin, prothrombin time, serum albumin, presence of ascites and encephalopathy) and MELD score 15 
(based on bilirubin, creatinine and INR) should be documented in those with severe liver disease. 16 
In neurological WD, symptoms on sequential evaluation remain the most critical outcome of 17 
therapeutic benefits.  Scales are essential to objectively quantify the severity of the disease and its 18 
impact on patient’s lifestyle.   Over the years, of the many rating scales that have been used, the  19 
Global Assessment Scale for Wilson’s Disease
137
 (GAS for WD) is the preferred scale since it assesses 20 
the neuropsychiatric, hepatic and osseomuscular changes and their impact on quality of life over the 21 
observation period. (Table 7)  22 
 23 
Long term Outcomes of Wilson’s Disease 24 
 25 
Wilson’s disease is well recognized as one of the treatable genetic disorders and early recognition and 26 
institution of therapy holds the key for good outcome. The response to therapy is dependent on 27 
various factors including drug compliance, duration/severity of symptoms at the time of institution of 28 
therapy. The Eurowilson Consortium in 2013,
139
 analysed the outcomes of patients on oral chelators in 29 
treatment of WD with a follow up of 5 to 30 years.  They noted that in 9/326 on Penicillamine, and in 30 
3/141 on trientine, liver transplantation was needed.   Overall improvement on therapy was 90% in 31 
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hepatic presentation and >55% with neurological presentation.  In studies that have observed the long 1 
term outcomes in large cohorts of patients, good improvement (including near normal quality of life, 2 
improvement in symptoms or stabilization) was noted in 85-93.5%
42,104,140,141
 3 
Most patients tend to have improvements up to 18-30 months after initiating therapy with good 4 
compliance, following which there is a plateau effect.  5 
Poor prognostic factors of patients of clinically severe neurological WD, included strong family history 6 
and severe MRI brain changes
142
. Despite severe neurological involvement, 50% of patients have good 7 
clinical improvement while on treatment. Non-responders to therapy show progressive, MRI worsening 8 
over time. 9 
 10 
Symptomatic management of Neuro Wilson’s Disease 11 
Dystonia: In addition to the de-coppering therapy, patients with moderate to significant dystonia need 12 
medications like trihexyphenidyl, tizanidine, baclofen, clonazepam, tetrabenzine for symptomatic 13 
treatment. 
143
Patients who have do not respond to the above or have  focal dystonia, botulinum toxin 14 
injections is the best option.
142
 Deep brain stimulation and lesionectomies of (globus pallidus interna 15 
has been performed with variable benefits, in those with refractory symptoms. Plasampharesis has 16 
been tried, for patients with refractory generalized dystonia, but is not part of standard protocol.  17 
Tremors:  Mild tremors do not require any specific interventions or only simple physical therapies.   In 18 
patients who have tremors affecting activities of daily living, drugs including propranolol, 19 
clonazepam, anticholinergics, topiramate, primodone have been used. 
143 
Pallidotomy ordeep brain 20 
stimulation can be considered in resistant tremors, with some beneficial effects.
 21 
Parkinsonism: Levodopa should be tried in all patients with parkinsonism, which might relieve 22 
symptoms. Other drugs of benefit include dopamine agonists, monoamine oxidase inhibitors, and 23 
amantadine.
143
 24 
Seizures:   Occur in about 6-8% of patients with Wilson’s disease, either at initial presentation or during 25 
the course of the disease. Therapy is on standard lines with anti-epileptic medications.   In view of 26 
associated hepatic dysfunction, anti-epileptics with first pass metabolism in liver should be avoided.    27 
Psychiatric Symptoms: While mild symptoms improve gradually with de-coppering, those with severe 28 
symptoms require medical interventions.  These include simple behavioural modifications to selective 29 
serotonin reuptake inhibitors , tricyclic antidepressants , serotonin-norepinephrine reuptake inhibitor 30 
and atypical antipsychotics (typical antipsychotics can precipitate extrapyramidal symptoms). Patients 31 
with aggressive manic symptoms or significant psychosis have been treated with electroconvulsive 32 
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therapies. There are no good randomized trials that have evaluated the efficacy of physical therapy. 1 
However isolated case reports and small case series suggest that physical therapy can be useful in 2 
cases with dystonia where stretching and splints can help prevent contractures and parkinsonism 3 
where gait and balance techniques can be benefit. There have been no randomized trials on the 4 
benefits of speech therapy for dysarthria. Neuromuscular electrical stimulation has been attempted in 5 
to improve dysphagia
145 
and it is standard practice to use a percutaneous endoscopic gastrostomy 6 
(PEG) in patients where swallowing is markedly affected to improve nutrition until the patient is able to 7 
swallow well. 8 
 9 
Dietary Copper in the management of Wilson’s Disease 10 
No prospective studies are available to define a cut-off level of copper in the diet of a patient with 11 
Wilson’s disease. Less than 1-2 mg/day of copper is widely acceptable and not specific for body weight 12 
or age (pediatric or adult).  The AASLD and EASL recommend avoiding foods with high concentration of 13 
copper in the first year of treatment.
1,2 
The rationale is justified as the body should not be overloaded 14 
with high dietary Cu during the critical first year of systemic chelation. However this opinion is based 15 
on two case reports of Wilson’s disease on vegetarian diet and bioavailability of copper in healthy 16 
subjects with dietary changes.
9 
The evidence to restrict Cu is weak. In developing countries, this 17 
recommendation has practical difficulties especially in vegetarians, since efforts to restrict dietary Cu to 18 
<2 mg/day results in protein intake being invariably reduced to 1-1.5 g/kg/d. This may be insufficient 19 
for a cirrhotic or advanced liver disease. Well-designed studies will be required to address this issue. It 20 
may be practical to restrict only very high copper containing foods like nuts, soy, liver and chocolates 21 
especially in the first year of chelation. Dairy, vegetables and fruits can be allowed unrestricted. Spices 22 
need not be restricted as effective intake is <5 g/d. Contrary to the wide belief, mushroom, animal 23 
meat, fish and poultry do not contain high copper. Table 8 shows food copper content in commonly 24 
used food items. The Cu content of foods is enhanced by drying, roasting, pickling, canning and adding 25 
preservatives, while boiling, milling, polishing and refining reduces the Cu content.
146
 If Cu pipe tubing 26 
systems is used for domestic supply, it is important to check whether the water supplied is soft or hard. 27 
Soft water is acidic and tends to solubilise the copper from the pipelines with considerable “leaching 28 
effect” in stored samples. Hard water is neutral to alkaline and copper is unaffected. Drinking water 29 
should ideally contain <0.1 part per million (0.1mg/L) of Cu. It is important to let the first 1-2 litres of 30 
water be flushed away before using for drinking purposes. While there is no evidence that boiling, 31 
simple filtration or reverse osmosis reduces the copper content, ion exchange methods used in 32 
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ultrafiltration may be effective. Bottled mineral water is estimated to contain <0.05mg/L Cu.
147
 1 
However further studies are required to confirm the same. Studies on Indian childhood cirrhosis have 2 
shown that copper content of boiled and 6 hour stored buffalo milk (98.4-98.8 μmol/L) and water (5.1-3 
5.4) in copper and brass vessels are higher than glass and aluminium vessels (milk: 1.8-2.0 and water 4 
0.9-1.1 μmol/L).
148
 5 
 6 
Additional treatment 7 
All patients need to be vaccinated for Hepatitis B and for Hepatitis A if they have not been previously 8 
exposed. Patients need to be managed for their complications of cirrhosis as per standard medical 9 
treatment. Alcohol and non steroidal anti-inflammatory drugs need to be avoided.  10 
 11 
Young women with Wilson’s disease  12 
Menstrual disturbances such as amenorrhea or oligomenorrhea are possibly related to disturbed 13 
hormonal activity. Impairment in conception and recurrent miscarriages in pregnancy have been 14 
reported. Women with undiagnosed and untreated WD have an increased rate of spontaneous 15 
abortions compared to women on treatment. (OR): 2.853 [95% CI: 1.634-4.982]).
149 
Proposed 16 
mechanisms include ovarian dysfunction due to decreased levels of estradiol with increased 17 
testosterone concentrations secondary to liver dysfunction and placental abnormalities like copper 18 
deposition. Higher spontaneous abortion noted in patients presented with neurologic manifestation 19 
compared with asymptomatic or hepatic or mixed manifestations (OR: 2.335, 95% confidence interval 20 
[CI]: 1.323-4.118).
150 
Patients on D-penicillamine and zinc showed lower spontaneous abortion rates 21 
compared to trientine (10% vs. 17% vs. 28%); but it was not statistically significant.
150 22 
 23 
Counselling the family  24 
Counselling also should address the risks of medication and risks of uncontrolled disease. Patients 25 
planning for pregnancy should have their copper status optimized before pregnancy. Also, the risk of 26 
0.5% of the child being affected needs to be explained. 27 
 28 
Maternal and pregnancy outcomes 29 
Several small case series and case reports in the last decade demonstrated a favourable outcome of 30 
pregnancies in patients treated with DP. Recent case reports with trientine and a case series of 29 WD 31 
patients exclusively treated with zinc showed uneventful maternal and pregnancy outcomes.
150,151
 A 32 
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recently published largest study of 282 pregnancies in 136 women with WD showed a favourable 1 
course of pregnancies in vast majority of treated patients. 
152 
In this study, presentation was 54% 2 
hepatic, 32% neurologic and 9% were neurohepatic. Forty-one percent were on D-penicillamine, 13% 3 
trientine, 7% zinc, 3% combination treatment and no therapy in 31%. Ninety- three percent had 4 
unchanged maternal outcome, 6% hepatic deterioration and 1% neurological deterioration. Seventy- 5 
two percent had healthy babies and 26% had spontaneous abortion. Abortion rates were 20-29% in all 6 
presentations but 40% with neurological. Abortions were least with zinc (10%) and highest if 7 
undiagnosed without therapy (41%) or paused therapy (36%) Monitoring of liver functions and 8 
neurologic symptoms throughout pregnancy is of utmost importance. The study reported slight 9 
alteration of biochemical values in 6% of cases, which subsided after delivery.
152
Treatment interruption 10 
during pregnancy has been reported to result in acute liver failure and appearance of neurologic 11 
symptoms. Safety of chelating agents in pregnancy has not been well established. Teratogenicity with 12 
high dose DP has been reported in animal studies and there are isolated case reports of connective 13 
tissue defects in humans.
153, 154
Over zealous chelation and maternal copper deficiency can also result in 14 
impaired fetal development. Recent studies showed relatively low rate of birth defects (3%) with DP.
152, 15 
155 
and the authors concluded that the overall benefits of continuing treatment outweigh the risks of 16 
treatment withdrawal. To avoid overchelation, the dose of DP and trientine may be reduced by 25-50% 17 
while zinc can be continued in the same dose.
152,156 
Patients whose diagnosis was made only during 18 
pregnancy should be started on standard dose of chelating agents considering the high copper burden. 19 
In women who are well controlled on chelation there is a suggestion that switching to zinc prior to 20 
conception decreases the risk of miscarriage or teratogenicity. Available data supports continuation of 21 
the previous chelator. Wound healing after Caesarean section or episiotomy may be delayed and 22 
therefore the dose of DP should be reduced toward the later weeks of pregnancy. After delivery, the 23 
dose of chelating agents should be increased to pre-pregnancy levels. Breast-feeding is not 24 
recommended in women on DP since it is excreted into breast milk and might be potentially harmful to 25 
the infant. There is scant data on safety of trientine and zinc in breast feeding. Detailed studies 26 
regarding contraception have not been performed so far. Spermicidal agents, barrier methods and 27 
progesterone only preparations are advisable for contraception in patients with WD. Estrogen 28 
containing pills may interfere with biliary copper excretion and some of the intrauterine devices 29 
contain copper. 30 
 31 
Newer therapies 32 
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Studies in murine models recently reveal that genetic WD mice carrying a corrective adenoviral vector 1 
containing human ATP7B DNA can bring long-term metabolic control and correction of copper 2 
metabolism.
157 
Significant improvement in liver injury (biochemical and histological), ceruloplasmin 3 
levels, urinary copper excretion, hepatic copper load and increase in hepatic ATP7B expression by 4 
immunostaining has been documented. Cell therapy to repopulate the liver with healthy hepatocytes 5 
including the reconstitution of bile canalicular network has been tried.
158 6 
 7 
CONSENSUS STATEMENTS ON TREATMENT OF WILSON’S DISEASE  8 
Drug therapy 9 
1. A chelating agent should be used for symptomatic patients with hepatic Wilson’s disease. D-10 
penicillamine is preferred due to easy availability, cost and efficacy.  (Strength-1, Level of evidence-B) 11 
2. Pre-symptomatic patients / those with hepatic disease on maintenance therapy / symptomatic 12 
patients with neuro- Wilson’s disease can be treated with zinc or chelating agent (Strength-1, Level of 13 
evidence -A) 14 
 3. Lifelong treatment is necessary unless the patient has had a liver transplant (Strength-1, Level of 15 
evidence -A)  16 
4. MARS and Total plasma exchange can be offered to patients with acute liver failure especially in 17 
presence of  encephalopathy and is a good bridge therapy to LT, should the patient not show prompt 18 
recovery. (Strength 1 and Level of evidence B)  19 
5. D-penicillamine is an effective chelator although associated with several side effects. (Strength 1, 20 
Level of evidence A)  21 
Liver Transplantation  22 
1. Liver transplantation is indicated in patients with fulminant presentation with hepatic 23 
encephalopathy or hemolytic crises (Strength 1, Level of evidence B) 24 
2.  New Wilson’s Index has been used as a predictor of LT (for both acute or chronic 25 
presentation) Rising bilirubin, advanced hepatic encephalopathy and acute hemolysis have 26 
been suggested as better predictors for LT and need validation. (Strength 1, Level of evidence 27 
B)  28 
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3. Living donor liver transplant from heterozygous sibling is effective and safe for both donor 1 
and recipient (strength 1, Level of evidence B)  2 
4. Liver transplantation is not indicated for in isolated severe neurological WD.  When the liver is 3 
also diseased, the decision should be individualized, since significant neurological disease is a 4 
predictor of poor outcome. (Strength 1 and Level of evidence B)  5 
Monitoring on treatment 6 
1. Careful clinical monitoring is necessary to determine benefit and adverse effects of the 7 
drugs.  Complete blood counts, urine analyses, liver function tests, 24 hour urinary copper and 8 
protein, serum free copper should be monitored frequently in the initial phase of therapy and 9 
at least 6-12 monthly thereafter. KF ring should be evaluated annually. (Strength-1, Level of 10 
evidence -B)  11 
2. GAS for WD is a comprehensive reliable and valid scale. It should be used to objectively 12 
assess the disability and to check the response to treatment on follow up especially in patients 13 
with Neuro-Wilson’s disease. (Strength 1, Level of evidence -B). 14 
 Drug therapy for neurological symptoms 15 
 1. Dystonia not responding to decoppering therapy anticholinergics and baclofen can be 16 
used. For those with refractory focal dystonia or residual dystonia, botulinum toxin injections 17 
can be considered (Strength 2, Level of evidence C).  18 
2. Primidone and propranolol can be used in patients with residual postural and action 19 
tremors, levodopa in parkinsonism and tetrabenezine in hyperkinesias (Strength 2, Level of 20 
evidence C). 21 
 3. Physical therapy and speech therapy have some role to play in rehabilitation of patients 22 
with neurological Wilson’s disease. (Strength 2, Level of evidence C). 23 
 4. In patients with severe dysphagia, PEG tubes are a temporary option till the dysphagia 24 
improves with chelation therapy. (Strength 2, Level of evidence C)  25 
Maternal and pregnancy outcomes 26 
1. Pregnancy in patients with WD is safe and most patients have successful outcome. 27 
[Strength I, Level of evidence  B]  28 
2. Patients with adequate copper control have better chances of successful pregnancies than 29 
untreated WD patients. Copper status of the patient should be optimized prior to pregnancy. 30 
[Strength I, Level of evidence B]  31 
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3. Treatment should be continued with previous chelation medication during pregnancy with 1 
dose reduction of chelators in later part of pregnancy. [Strength 2, Level of evidence B]. 2 
 4. The risk of birth defects in WD is generally low, which also applies for patients treated with 3 
chelating agents. [Strength I, Level of evidence B]  4 
Newer Therapies  5 
Newer therapies include hepatocyte transplant, stem cell transplant and gene therapy, which 6 
attempt to restore hepatobiliary copper excretion. However, these seem to be still in experimental 7 
phase. (Strength 2, Level of evidence C) 8 
 9 
 10 
  11 
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Figures titles and legends where relevant 
Figure 1: Circulation of copper in the body  
Figure 2: Golden brown Kayser-Fleisher (KF) ring 
Figure 3: Vacuous smile in Wilson’s disease 
Figure 4: MRI changes in Wilson’s disease  
Legend: A. Flair axial brain MRI showing hyperintensities in bilateral putamen and thalami 
with hypointensity of globus pallidi in a patient with neurological manifestations; B) T1W 
axial brain MRI showing hyperintensity of bilateral globus pallidi in a patient with hepatic 
form of WD; C) Flair axial brain MRI showing hyperintensities in dorsal midbrain and 
subcortical white matter signal changes in temporal region in a patient with neurological 
form of WD; D) T2W axial MRI brain depicting ‘face of giant panda’; E,F: Central pontine 
myelinolysis–like Pontine signals changes in WD in flair axial brain MRI.  
 
Figure 5: Elastosis perforans serpiginosa secondary to long term d-penicillamine use 
Legend: Multiple annular plaques seen over bilateral forearms with Hyperpigmented 
papules arranged at the periphery and few papules showing central small keratotic plugging 
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Table 1. Clinical manifestations of Wilson’s disease  
Hepatic  Asymptomatic hepatomegaly, persistently elevated transaminases, 
Acute hepatitis, Chronic hepatitis, Cirrhosis (compensated and 
decompensated), Acute liver failure, Acute on chronic liver failure, 
Fatty liver, Isolated splenomegaly, Cholelithiasis 
Neuropsychiatric  Tremors,  Dystonia, Parkinsonism, Choreoathetosis, 
Seizures, Dysarthria, Drooling, Clumsiness, Incoordination,  Gait 
disturbance, Behavioural changes, Deteriorating school performance, 
Depression, Anxiety, Psychosis  
Osseomuscular  Arthralgia, Arthritis, Fractures, osteoporosis, osteomalacia, 
chondromalacia 
Hematological  Hemolytic anemia, Thrombocytopenia, Pancytopenia, Coagulopathy  
Ocular  Kayser-Fleischer rings, Sunflower cataracts  
Renal  Renal stones, Renal tubular acidosis, Fanconi syndrome 
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Table 2: Studies with prevalence of various clinical manifestations of Wilson’s 
disease 
Study Hepatic Neuro-psychiatric  Pre-
symptomatic 
Other  
Lee BH, et al 
(n=245)
69
 
134 (54.8%) 55 (22.4%) 55 (22.4%) 1 (0.4%) 
[Osseomuscular] 
Taly AB, et al 
(n=282)
42
 
42 (15%) 219 (77.6%)  
Neuro 195 
Hepato-neuro 10, 
psychiatric 7, 
others 7] 
15 (5.4%) 6 (2%) 
[Osseomuscular] 
Walshe JM. 
(n=217)
40
 
94 (43.1%) 97 (44%) 24 (11%) 2 (0.9%) 
[Osseomuscular] 
Cheng N, et al 
(n=1222)
70
 
450 (37%) 592 (48.5%) 31 (2.5%) 149 (12%) [Neuro-
visceral] 
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Table 3: Modified Leipzig scoring system for diagnosis of Wilson’s disease 
KF rings 
Present 
Absent 
 
2 
0 
Serum ceruloplasmin 
Normal (> 20 mg/dl ) 
0 – 5 mg/dl  
6 -11 mg/dl 
11-20 mg/dl 
 
 
0 
3 
2 
1 
24 hour urinary copper (in the absence of acute hepatitis) 
>100 mcg  
40-100 
<40 mcg 
 
2 
1 
0 
Coombs-negative hemolyticanemia with liver disease 
Present 
Absent 
 
1 
0 
Mutational analysis 
On both chromosomes detected 
On one chromosome detected 
No mutation detected/ test not done 
 
4        
1  
0 
Liver biopsy for histology  S/O WD 
Orcein or Rhodanine-positive granules 
 
 
1 
 
 
Neurobehavioral symptoms  
Typical features on MRI BRAIN  
2 
1 
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Any one of the following 
Family history or 
Sibling death from liver disease/Neurological 
disease suggestive of WD 
 
 
1 
 
TOTAL SCORE   Evaluation 
≥4 or more              Diagnosis established  
3    Diagnosis possible, more tests needed 
<2    Diagnosis very unlikely 
 
WD – Wilson’s disease 
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Table 4: Adverse Effects of Drugs used in treatment of Wilson’s disease 
Name of drug Side Effects 
D-penicillamine- Early: (1-3 weeks) Hypersensitivity 
Fever, cutaneous eruptions, lymphadenopathy, neutropenia, 
thrombocytpenia and proteinuria  
 
Late: (3 weeks to 3 months) Hypersensitivity 
a) Renal: Lupus like syndrome (proteinuria, hematuria, positive 
ANA)  
b) Lung: Good pasture syndrome 
c) Bone Marrow: severe thrombocytopenia, total aplasia 
d) Skin: pemphigus, pemphigoid lesions involving skin, mouth, 
vagina, buccal ulcerations, apthous stomatitis, hair loss 
e) Eye: optic neuritis. 
 
Very Late (after 1 year ) 
Nephrotoxicity, severe allergy on restarting drug, myasthenia 
gravis, polymyositis (<1%), loss of taste, immunoglobulin A 
depression, retinitis, hepatotoxicity (transaminitis), copper 
depletion leading to neutropenia, sideroblasticanemia and 
hemosiderosis 
 
Direct Dose dependent: 
a) Pyridoxine deficiency  
b) Skin: Elastosisperforansserpenginosa, lichen planus, progeria 
like skin changes, d-penicillaminedermopathy a brownish 
discolouration of skin secondary to trauma related 
subcutaneous bleed  
c) Mammary hypertrophy  
 
Neurological deterioration: Incidence ranges from  10-50% 
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Triethylenetetramine 
hydrochloride/  
Trientene 
 
 Few side effects 
 No hypersensitivity described  
 Fixed drug eruption reported in one patient. 
 Chelates Iron: should not be co-administered with Iron  
 Bone marrow depression 
 Sideroblasticanemia: reversible (Iron and copper Deficiency ) 
 Hemorrhagic gastritis, Loss of taste and skin rash 
  
 Neurological deterioration is less common 
  
ANA: anti-nuclear antibody 
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Table 5: New Wilson’s index for predicting survival 
75
 
Score Bilirubin 
(mg/dl) 
INR AST(IU/L) WCC 
(10
9
/L) 
0 0 – 5.8 0 – 1.29 0 – 100 0 – 6.7 
1 5.9 – 8.7 1.3 – 1.6 101 – 150 6.8 – 8.3 
2 8.8 – 11.6 1.7 – 1.9 151 – 200 8.4 – 10.3 
3 11.7 – 17.5 2.0 – 2.4 201 – 300 10.4 – 15.3 
4 >17.6 >2.5 >300 >15.4 
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Table 6: Interpretation of tests used in monitoring drug treatment of Wilson’s 
disease 
 Zinc D-penicillamine / Trientine 
Initial treatment U Cu 100-500 µg/d 
S free Cu > 25 µg/dL 
U Zn > 2000 µg/d 
U Cu >500µg/d 
S free Cu > 25 µg /dL 
Good control 
(Maintenance) 
U Cu <75µg/d 
S free Cu 10-15 µg /dL 
U Cu 200-500 µg/d 
S free Cu 10-15µg /dL 
Non-compliance/ 
Inadequate dose 
U Zn <2000µg/d 
S free Cu >15µg /dL 
U Cu < 200 µg/d 
U Cu > 500 µg/d 
S free Cu >15µg /dL 
Over-treatment U Cu < 25 µg/d 
S. free Cu < 5 µg /dL 
 
U Cu < 200 µg/d 
S. free Cu < 5 µg /dL 
To document therapeutic efficiency, urinary copper excretion after 2 days of D-d-
penicillamine cessation should be < 50µgin 24 hours. If more , suggest poor 
compliance
136
 
U Cu = 24 hour urinary copper, U Zn = 24 hour urinary zinc, S. free Cu =Serum free 
copper, DP = D penicillamine 
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Table 7: Global Assessment Scale for Wilson’s disease
 
Tier  Areas of Assessment 
Tier 1 Domains 
Scored from 0-5 in 
each domain based 
on impact on 
activities of daily 
living  
Domain  
Liver Clinical, biochemical and abdominal 
ultrasound evidence for liver disease 
Cognition and 
Behaviour 
Intellectual decline, depression and 
psychosis 
Motor  Motor impairment on examination 
Osseomuscular Joint or muscle involvement by clinical 
examination and radiographs 
Tier 2  
Items 1-13 scored 
from 0-4 based on 
clinical severity 
1. Wilson’s facies 
2. Scholastic 
performance  
3. Depression 
4. Psychosis 
5. Dystonia 
6. Tremor  
7. Chorea 
8. Parkinsonism  
9. Speech  
10. Swallowing   
11. Salivation 
12. Posture and gait  
13. Kayser Fleischer ring 
Tier 2 Item 14 is 
scored on presence 
or absence of 
uncommon 
manifestations 
(each scored as 1 
point with a 
maximum of 4 
points. 
 
Emotional lability 
Seizures over preceding 1 month 
Myoclonus 
Stereotypy  
Tics 
Pyramidal signs  
Eye movement abnormalities 
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* In the liver domain, the scores range from no liver disease ever (L0) through active 
liver disease (L2), compensated (L3), decompensated liver disease (L4) to potentially 
life threatening disease (L5) 
Greater weightage is given to Wilson’s facies and K-F rings that are characteristic 
features of Wilsons disease.  
 
 
Table 8: The copper content (mg) in daily dietary items per 100 g edible portion 
(Adapted from Indian Food Composition Table, National Institute of Nutrition 
2017) 
 
Low copper food items 
(copper content <1mg/100g edible portion) 
High copper food items  
(copper content >1mg/100g edible portion) 
Rice (whole, puff, flakes) (0.23-0.27) Red gram (1.14) 
Wheat (whole grain, flour, semolina, vermicelli 
and noodles) (0.17-0.48)  
Soyabean (1.29) 
Maize and products (0.11-0.45) Lotus stem, water chestnut (1.2-1.3) 
Barley and millet (0.43-0.67) All nuts (1.1-2.2) 
All legumes except red gram (0.6-0.97) Cumin, coriander, black pepper and mace (1.1-1.6) 
All vegetables (0.1-0.4) Liver (6.0) 
Mushroom (0.09) Oyster (3.4) 
All fruits (0.1-0.6) Duck meat (1.0) 
All spices (except cumin, coriander, black pepper 
and mace) (0.1-0.6) 
Cocoa (3.8) 
Fish, prawns, chicken, red meat (0.1-0.5)  
Egg (0.07)  
Milk and dairy products (0.03-0.1)  
Coffee; tea (0.2-0.5)  
Jaggery (0.03)  
The authors cannot verify the Cu content of the following food items: gram flour, barley, oats, protein 
energy powder, soy milk, soy products, sauces, cheese and table salt. Gram flour and barley are likely to 
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contain higher Cu content from their original pulses as the process requires drying and roasting. Most 
protein energy powders are derived from soy sources. All soy products, sauces and cheese undergo 
fermentation and contain preservatives thereby increasing the Cu content. 
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